Arvinas Inc
NASDAQ:ARVN

Watchlist Manager
Arvinas Inc Logo
Arvinas Inc
NASDAQ:ARVN
Watchlist
Price: 18 USD -2.6% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Arvinas Inc?
Write Note

Relative Value

The Relative Value of one ARVN stock under the Base Case scenario is 11.57 USD. Compared to the current market price of 18 USD, Arvinas Inc is Overvalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARVN Relative Value
Base Case
11.57 USD
Overvaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
14
Median 3Y
13.6
Median 5Y
28.4
Industry
2.5
Forward
4.6
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-10
Industry
21.8
Forward
-5.6
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-8.1
Industry
16.1
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-8
Industry
23.8
vs History
69
vs Industry
24
Median 3Y
3.2
Median 5Y
4.5
Industry
2.1
vs History
76
vs Industry
28
Median 3Y
5.4
Median 5Y
19.6
Industry
2.7
Forward
0.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
55
Median 3Y
-2.2
Median 5Y
-6
Industry
13.5
Forward
-0.5
vs History
vs Industry
52
Median 3Y
-2.2
Median 5Y
-5.8
Industry
16.8
Forward
-0.4
vs History
vs Industry
52
Median 3Y
-1.1
Median 5Y
-3
Industry
15.2
vs History
vs Industry
39
Median 3Y
-1.1
Median 5Y
-3
Industry
19.3
vs History
vs Industry
4
Median 3Y
14.6
Median 5Y
32.5
Industry
1.9

Multiples Across Competitors

ARVN Competitors Multiples
Arvinas Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arvinas Inc
NASDAQ:ARVN
1.2B USD 4.4 -2.4 -0.2 -0.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP 4.1 31.5 169.4 253.9
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
US
Arvinas Inc
NASDAQ:ARVN
Average P/S: 382 942.4
4.4
186%
0
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
US
Arvinas Inc
NASDAQ:ARVN
Average P/E: 32.4
Negative Multiple: -2.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Arvinas Inc
NASDAQ:ARVN
Average EV/EBITDA: 459.6
Negative Multiple: -0.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Arvinas Inc
NASDAQ:ARVN
Average EV/EBIT: 2 011.3
Negative Multiple: -0.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top